US · IPHA · BIOTECHNOLOGY
Innate Pharma S.A. (IPHA) intrinsic value and stock valuation
$0.86as of 2026-11-21 · Mkt cap 166.21M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Innate Pharma S.A. DCF and intrinsic value
InvestorsCraft values IPHA with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from IPHA’s statements →
Innate Pharma S.A. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Nuvectis Pharma, Inc. (NVCT) $19.39
- Compugen Ltd. (CGEN) $1.84
- Corbus Pharmaceuticals Holdings, Inc. (CRBP) $2.06
- Molecular Partners AG (MOLN) $2.53
- Milestone Pharmaceuticals Inc. (MIST) $0.37
- Cardiff Oncology, Inc. (CRDF) $0.85
- Elicio Therapeutics, Inc. (ELTX) $1.45
- Rani Therapeutics Holdings, Inc. (RANI) $0.51
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $2.79M | $12.6M | $51.9M | $57.7M | $12.1M |
| Operating income | -$-53.42M | -$-51.58M | -$-12.67M | -$-57.42M | -$-47.83M |
| Net income | -$-49.18M | -$-49.47M | -$-7.57M | -$-58.1M | -$-52.81M |
| EPSd | -$-549.99K | -$-610.36K | -$-90K | -$-729.53K | -$-663.94K |
| Operating cash flow | -$-32.56M | -$-6.9M | -$-32.56M | -$-19.15M | -$-58.46M |
| Capital expenditure | -$-2.35M | -$-390K | -$-2.35M | -$-1.12M | -$-1.33M |
| Free cash flow | -$-34.91M | -$-7.29M | -$-34.91M | -$-20.28M | -$-59.79M |
| Total assets | $62.7M | $111.1M | $175.2M | $207.9M | $267.5M |
| Total debt | $22.6M | $31M | $39.9M | $42.3M | $44.3M |
| Net debt | -$-5.52M | -$-35.4M | -$-30.71M | -$-41.97M | -$-59.51M |
| Total equity | -$-21.69M | $8.83M | $51.9M | $54.2M | $107.4M |
| Cash and short-term investments | $34.3M | $80.8M | $92.5M | $101.5M | $119.8M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $2.79M | $12.6M | $51.9M | $57.7M | $12.1M |
| Cost of revenue | $0.00 | $52M | $56M | $51.7M | $47M |
| Gross profit | $2.79M | $12.6M | $5.62M | $6.01M | -$-22.3M |
| Research and development expenses | $43.6M | $52M | $56M | $51.7M | $47M |
| Selling, general and administrative expenses | $11M | $11.9M | $11.8M | $14.5M | $25.5M |
| Other expenses | $1.59M | $280K | -$-49.48M | -$-2.7M | -$-47M |
| Operating expenses | $56.2M | $64.2M | $18.3M | $63.4M | $25.5M |
| Cost and expenses | $56.2M | $64.2M | $74.3M | $115.1M | $59.9M |
| Interest income | $1.32M | $2.44M | $3.18M | $550K | $330K |
| Interest expense | $440K | $570K | $640K | $290K | $310K |
| Depreciation and amortization | $5.09M | $1.99M | $5.09M | $45.4M | $4.6M |
| Ebitda | -$-43.65M | -$-46.91M | -$-1.84M | -$-12.28M | -$-43.23M |
| Operating income | -$-53.42M | -$-51.58M | -$-12.67M | -$-57.42M | -$-47.83M |
| Total other income/expenses, net | $4.25M | $2.1M | $5.1M | -$-550K | $2.35M |
| Income before tax | -$-49.18M | -$-49.47M | -$-7.57M | -$-57.97M | -$-45.48M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$-49.18M | -$-49.47M | -$-7.57M | -$-58.1M | -$-52.81M |
| Weighted average shares outstanding | $89.4M | $81.1M | $84.1M | $79.6M | $79.5M |
| Weighted average diluted shares outstanding | $89.4M | $81.1M | $84.1M | $79.6M | $79.5M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $34.3M | $80.8M | $92.5M | $101.5M | $119.8M |
| Net receivables | $7.61M | $1.64M | $46.5M | $3.14M | $1.66M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $46.7M | $85.7M | $148M | $139.8M | $138.3M |
| Property, plant and equipment, net | $4.35M | $5.13M | $6.32M | $8.54M | $10.2M |
| Goodwill and intangible assets | $0.00 | $0.00 | $420K | $1.56M | $44.2M |
| Long-term investments | $10.7M | $10.3M | $9.8M | $35.1M | $39.9M |
| Total non-current assets | $16M | $25.3M | $27.2M | $68M | $129.2M |
| Total assets | $62.7M | $111.1M | $175.2M | $207.9M | $267.5M |
| Accounts payable | $15M | $7.92M | $8.56M | $13.7M | $14.7M |
| Short-term debt | $8.8M | $8.71M | $8.94M | $2.1M | $30.8M |
| Deferred revenue | $2.82M | $620K | $5.87M | $6.56M | $12.5M |
| Total current liabilities | $36.6M | $33M | $39.6M | $41.3M | $79.9M |
| Long-term debt | $13.8M | $22.3M | $31M | $40.2M | $13.5M |
| Deferred revenue, non-current | $0.00 | $2.83M | $4.62M | $7.92M | $25.4M |
| Total non-current liabilities | $47.8M | $69.2M | $83.7M | $112.4M | $80.2M |
| Capital lease obligations | $380K | $380K | $830K | $2.06M | $2.82M |
| Total liabilities | $84.4M | $102.2M | $132.3M | $153.7M | $160.1M |
| Common stock | $4.69M | $4.19M | $4.04M | $4.01M | $3.98M |
| Retained earnings | -$-435.36M | -$-386.36M | -$-336.89M | -$-330.32M | -$-272.21M |
| Accumulated other comprehensive income (loss) | $1.12M | $30K | $490K | $820K | $460K |
| Total equity | -$-21.69M | $8.83M | $51.9M | $54.2M | $107.4M |
| Total investments | $16.9M | $24.7M | $31.7M | $52.4M | $56M |
| Total debt | $22.6M | $31M | $39.9M | $42.3M | $44.3M |
| Net debt | -$-5.52M | -$-35.4M | -$-30.71M | -$-41.97M | -$-59.51M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-7.57M | -$-49.47M | -$-7.57M | -$-58.1M | -$-52.81M |
| Depreciation and amortization | $5.09M | $1.99M | $5.09M | $45.4M | $4.6M |
| Stock-based compensation | $4.26M | $3.94M | $4.26M | $4.25M | $2.62M |
| Change in working capital | -$-32.09M | $47.7M | -$-32.09M | -$-12.5M | -$-9.88M |
| Accounts receivable | $0.00 | $51.8M | -$-13.67M | -$-4.2M | $3.39M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | -$-6.27M |
| Accounts payable | $0.00 | $0.00 | -$-3.89M | -$-7.66M | -$-950K |
| Net cash provided by operating activities | -$-32.56M | -$-6.9M | -$-32.56M | -$-19.15M | -$-58.46M |
| Investments in property, plant and equipment | -$-350K | -$-390K | -$-350K | -$-1.12M | -$-1.33M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $10K |
| Net cash used for investing activities | $20.6M | $9.2M | $20.6M | $1.88M | -$-920K |
| Common stock issued | $400K | $2.93M | $400K | $200K | $500K |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-1.97M | -$-6.01M | -$-1.97M | -$-1.83M | $26.8M |
| Net change in cash | -$-13.62M | -$-4.21M | -$-13.62M | -$-19.53M | -$-33.04M |
| Cash at end of period | $70.6M | $66.4M | $70.6M | $84.2M | $103.8M |
| Operating cash flow | -$-32.56M | -$-6.9M | -$-32.56M | -$-19.15M | -$-58.46M |
| Capital expenditure | -$-2.35M | -$-390K | -$-2.35M | -$-1.12M | -$-1.33M |
| Free cash flow | -$-34.91M | -$-7.29M | -$-34.91M | -$-20.28M | -$-59.79M |
Line items
Line items
Line items
About Innate Pharma S.A.
Innate Pharma S.A. is a biotechnology firm, founded in 1999 and headquartered in Marseille, France, that specializes in the discovery, development, and market introduction of therapeutic antibodies. The company primarily targets oncology indications across France and internationally, with some programs also addressing inflammatory diseases and viral infections. Its clinical-stage pipeline features several key assets: Lacutamab (IPH4102): An anti-KIR3DL2 antibody undergoing Phase II trials for cutaneous T-cell and peripheral T-cell lymphoma, and also for refractory Sézary syndrome. Monalizumab: An immune checkpoint inhibitor currently in Phase III clinical trials for various advanced solid tumors, including colorectal, lung, and head and neck cancers. Avdoralimab (IPH5401): A monoclonal antibody designed to block C5a binding to C5aR1, which is in Phase II development for COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory conditions. IPH5201: A blocking antibody in Phase I trials, focused on the CD39 immunosuppressive pathway. IPH5301: An anti-CD73 antibody developed to enhance anti-tumor immunity by targeting the immunosuppressive adenosine pathway. IPH6101: An NKp46-based NK cell engager being evaluated for the generation of up to two bispecific NK cell engagers. Innate Pharma also maintains an active preclinical pipeline, including IPH43 (an anti-MICA/B antibody drug conjugate), an Anti-Siglec-9 antibody program, IPH65 (a proprietary tetraspecific antibody), IPH25 (a checkpoint inhibitor), and the IPH62 and IPH64 programs. The company has established strategic licensing and collaboration agreements with major industry players such as AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech, alongside a co-development and license agreement with MedImmune Limited.
- CEO
- Jonathan E. Dickinson
- Employees
- 163
- Beta
- 0.88
Explore
Frequently asked questions
What is the intrinsic value of Innate Pharma S.A. (IPHA)?
InvestorsCraft does not currently publish an intrinsic value for IPHA. How the IC value is calculated.
Is IPHA undervalued?
InvestorsCraft does not publish an undervaluation signal for IPHA at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.